Overall, our findings confirm that tumor biology—particularly proliferation index and hormone receptor status—was the main determinant of therapeutic decisions, underscoring the importance of reassessing biomarkers after surgery and reinforcing the paradigm of individualized, biology-driven treatment in breast cancer. The gene discussed is NR4A1; the disease is breast carcinoma.